Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 01G in untreated stage IV NSCLC
MOH_2025-01-21_013788Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of pembrolizumab and patritumab deruxtecan, sponsored by Merck & Co. Started Nov 2024; status: recruiting.
02
Drugs
pembrolizumabpatritumab deruxtecan
Beyond the preview
Go deeper on MOH_2025-01-21_013788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-01-21_013788.